<DOC>
	<DOCNO>NCT02230033</DOCNO>
	<brief_summary>The purpose study assess effect multiple dose itraconazole gemfibrozil pharmacokinetics ( study way drug enters leave blood tissue time ) JNJ-56021927 metabolite ( JNJ 56142060 JNJ-56142021 ) healthy male participant .</brief_summary>
	<brief_title>Study Assess Drug-Drug Interaction Between Itraconazole Gemfibrozil JNJ-56021927</brief_title>
	<detailed_description>This single-dose , single-center , open-label ( people know identity intervention ) , 3-treatment , randomize ( study medication assign participant chance ) parallel-group ( medical research study compare response two group participant receive different intervention [ treatment ] ) study . The study consist Screening Phase ( , 21 day study commences Day 1 ) ; open-label treatment Phase end-of-study early withdrawal assessment . All participant randomly assign 1 3 treatment , , Treatment A ( single dose JNJ-56021927 Day 1 ) , Treatment B ( 200 milligram [ mg ] itraconazole daily Day 1 Day 32 along single dose JNJ-56021927 Day 4 ) , Treatment C ( 600 mg gemfibrozil twice daily Day 1 Day 32 along single dose JNJ-56021927 Day 4 ) . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . The maximum duration participation study per participant approximately 78 day ( Treatment A ) 81 day ( Treatment B C ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>Must agree use adequate contraception method deem appropriate Investigator specify protocol , always use condom sexual intercourse , donate sperm study 3 month receive study drug Body mass index 18 30 kilogram ( kg ) per square meter , body weight less 50 kg Blood pressure ( supine 5 minute ) 90 140 millimeter mercury ( mm Hg ) systolic , high 90 mm Hg diastolic A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function Screening , include : Pulse rate 45 99 beat per minute ( bpm ) ; QTc interval less equal ( &lt; = ) 450 millisecond ; QRS interval le ( &lt; ) 120 millisecond ; PR interval &lt; 220 millisecond ; morphology consistent healthy cardiac conduction function Nonsmoker within previous 2 month ( calculate first dose ) History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry urinalysis Screening admission study center deem appropriate Investigator Medical history gallbladder disease ( cholecystitis , cholelithiasis , cholecystectomy ) Presence sexual dysfunction medical condition would affect sexual function Screening serum testosterone level &lt; 200 nanogram/deciliter ( ng/dL ) Previous history photoallergy phototoxic reaction treatment fibrates</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>JNJ-56021927</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Gemfibrozil</keyword>
</DOC>